Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus famitinib in advanced solid tumors
CTR20200720Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, famitinib in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Apr 2020; status: completed.
02
Drugs
anlotinibfamitinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20200720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200720.